Vol 8, Supplement 1 (October 22, 2019): Chinese Clinical Oncology

Editorial

Ensartinib (X-396) a novel drug for anaplastic lymphoma kinase-positive non-small cell lung cancer patients: we need smart trials to avoid wasting good bullets
Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S1
Digging into lorlatinib resistance in ALK-positive lung cancer: an editorial
Francesco Facchinetti, Marcello Tiseo
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S2
Does bisphosphonate treatment reduce the risk of future cancer?
Michael Pazianas, Bo Abrahamsen
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S3
Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC
Tianhong Li, Weijie Ma, Eddie C. Tian
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S4
Perineural invasion in oral cancer: challenges, controversies and clinical impact
Sabrina Daniela da Silva, Luiz Paulo Kowalski
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S5
Recent changes in the American Joint Commission Cancer staging of human papilloma virus related oropharyngeal cancer: validating the present and envisioning the future
Brett A. Miles
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S6
The dawn of a universal language for an emerging malignancy
Junichi Shindoh
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S7
The 8th Edition of the American Joint Committee on Cancer (AJCC8) Staging Manual: any improvement in the prognostication of oral tongue cancer?
Alhadi Almangush, Tuula Salo
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S8
Considering sarcoma staging systems and their implications to personalized care
Rick L. Haas, Michiel A. J. van de Sande
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S9
Occult breast cancer: the uncommon presentation of a common disease
Angela Toss, Luca Moscetti, Stefano Cascinu
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S10
Breast cancer prognostic staging and internal mammary lymph node metastases: a brief overview
Jennifer K. Plichta
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S11
Staging systems and nomograms in soft tissue sarcoma: outcome prediction by categorization or personalization?
William W. Tseng, Sandro Pasquali, James S. Hu, Lawrence R. Menendez, Alessandro Gronchi
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S12
Unlocking the potential with the use of check-point inhibitor immunotherapies in metastatic prostate cancer
Swaroop Revannasiddaiah, Ishu Gupta, Santhosh Kumar Devadas
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S13
Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?
Francesco Ricci, Christophe Le Tourneau
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S14
What can National Registry data tell us about occult breast cancer?
John Benjamin Wild, Steven Thrush, Raghavan Vidya
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S15
Impact of hypochloremia in resected colorectal cancer patients
Mai Tsutsui, Seiichiro Yamamoto
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S16
A step ahead on CTHRC1, and not just reinventing the wheel!
Siddharth Turkar, Anant Ramaswamy, Vikas Ostwal
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S17

Editorial Commentary

Relevant changes in the AJCC 8th edition staging manual for oral cavity cancer and future implications
Luiz Paulo Kowalski, Hugo Fontan Köhler
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S18
AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time?
Daniel H. Ahn, Tanios Bekaii-Saab
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S19
Bevacizumab is more effective in nasopharyngeal carcinoma patients with lower maximum radiation dose to the temporal lobe
Adam Garsa, Jennifer C. Ho, Chaosu Hu, Eric L. Chang
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S20
Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma
Veronica Mollica, Vincenzo Di Nunno, Francesco Massari
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S21
Chemotherapy of pancreatic cancer in patients with poor performance
Dominik Schulz, Hana Algül
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S22
Perioperative safety in patients with resectable synchronous colorectal liver metastases
Lucas D. Lee, Y. Nancy You
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S23
Immune subgroups and the tumor microenvironment as a potential new biomarker to assess response to immunotherapy
Shawn Kothari, Everett E. Vokes
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S24
More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine
Ibrahim Aldoss, Guido Marcucci
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S25
Is it time for a specific score for venous thromboembolism risk assessment for non-solid tumors?
Ariane Vieira Scarlatelli Macedo, Eduardo Ramacciotti
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S26

Letter to the Editor

A closer look at the staging of soft tissue sarcomas in an era of personalized medicine
Aileen C. Johnson, Kenneth Cardona
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S27

Obituary

In memory of Dr. Henry T. Lynch
Daniel G. Haller
Chinese Clinical Oncology
 2019;
8
(Suppl 1)
:S28

Disclosure:

The supplement was published without any sponsorship or funding.